IS5465A - Indazól bíóísóster umskipting á katekóli í meðferðalega virkum efnasamböndum - Google Patents

Indazól bíóísóster umskipting á katekóli í meðferðalega virkum efnasamböndum

Info

Publication number
IS5465A
IS5465A IS5465A IS5465A IS5465A IS 5465 A IS5465 A IS 5465A IS 5465 A IS5465 A IS 5465A IS 5465 A IS5465 A IS 5465A IS 5465 A IS5465 A IS 5465A
Authority
IS
Iceland
Prior art keywords
bioisosterone
indazole
catechol
conversion
active compounds
Prior art date
Application number
IS5465A
Other languages
English (en)
Inventor
Marfat Anthony
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of IS5465A publication Critical patent/IS5465A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IS5465A 1997-11-04 2000-04-19 Indazól bíóísóster umskipting á katekóli í meðferðalega virkum efnasamböndum IS5465A (is)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US6422997P 1997-11-04 1997-11-04
US6422897P 1997-11-04 1997-11-04
US6419897P 1997-11-04 1997-11-04
US6418797P 1997-11-04 1997-11-04
US6402497P 1997-11-04 1997-11-04
PCT/IB1998/001710 WO1999023077A1 (en) 1997-11-04 1998-10-26 Indazole bioisostere replacement of catechol in therapeutically active compounds

Publications (1)

Publication Number Publication Date
IS5465A true IS5465A (is) 2000-04-19

Family

ID=27535645

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5465A IS5465A (is) 1997-11-04 2000-04-19 Indazól bíóísóster umskipting á katekóli í meðferðalega virkum efnasamböndum

Country Status (29)

Country Link
US (1) US6391872B1 (is)
EP (1) EP1028946A1 (is)
JP (1) JP2001521926A (is)
CN (1) CN1284948A (is)
AP (1) AP910A (is)
AR (1) AR013746A1 (is)
AU (1) AU754734B2 (is)
BG (1) BG104450A (is)
BR (1) BR9813926A (is)
CA (1) CA2309150A1 (is)
CZ (1) CZ20001621A3 (is)
DZ (1) DZ2640A1 (is)
EA (1) EA200000488A1 (is)
HR (1) HRP20000253A2 (is)
HU (1) HUP0004150A3 (is)
ID (1) ID23921A (is)
IL (1) IL135900A0 (is)
IS (1) IS5465A (is)
MA (1) MA26563A1 (is)
NO (1) NO20002129L (is)
NZ (1) NZ503918A (is)
OA (1) OA11354A (is)
PE (1) PE129199A1 (is)
PL (1) PL340753A1 (is)
SK (1) SK6252000A3 (is)
TN (1) TNSN98200A1 (is)
TR (1) TR200001234T2 (is)
WO (1) WO1999023077A1 (is)
YU (1) YU25000A (is)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200001256T2 (tr) * 1997-11-04 2000-11-21 Pfizer Products Inc. Terapötik olarak aktif bileşimler.
UA71971C2 (en) 1999-06-04 2005-01-17 Agoron Pharmaceuticals Inc Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
PE20010306A1 (es) * 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
US7141581B2 (en) 1999-07-02 2006-11-28 Agouron Pharmaceuticals, Inc. Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
JP2001031549A (ja) * 1999-07-14 2001-02-06 Pola Chem Ind Inc 真皮コラーゲン線維束再構築剤及びそれを含有する化粧料
US6432979B1 (en) 1999-08-12 2002-08-13 American Cyanamid Company Method of treating or inhibiting colonic polyps and colorectal cancer
DK1202746T3 (da) * 1999-08-12 2007-01-02 Wyeth Corp NSAID- og EGFR-kinaseinhibitorerholdigt præparat til behandling eller inhibering af colonpolypper og colorektal cancer
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
HN2001000008A (es) 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
US7005443B1 (en) * 2000-03-17 2006-02-28 Alcon, Inc. 5-Hydroxy indazole derivatives for treating glaucoma
BR0110302A (pt) 2000-04-18 2003-01-14 Agouron Pharma Compostos de pirazol para inibição de proteìnas cinase, sal e pró-droga farmaceuticamente aceitável, metabólito farmaceuticamente ativo ou sal farmaceuticamente aceitável de metabólito, composição farmacêutica, método de tratamento de condição doentia em mamìferos mediada pela atividade de proteìna cinase, método de modulação ou inibição da atividade de um receptor de proteìna cinase
WO2002083648A1 (fr) * 2001-04-16 2002-10-24 Eisai Co., Ltd. Nouveau compose a base de 1h-indazole
MXPA04002562A (es) 2001-09-19 2004-05-31 Altana Pharma Ag Combinacion de un pde-4 y nsaid.
WO2003024456A1 (en) * 2001-09-20 2003-03-27 Eisai Co., Ltd. Methods for treating and preventing migraines
US20050163438A1 (en) * 2002-02-13 2005-07-28 Sander Aloysius F.M. Integrated semiconductor optical device, method and apparatus for manufacturing such a device
US7972632B2 (en) 2003-02-28 2011-07-05 Unigen Pharmaceuticals, Inc. Identification of Free-B-Ring flavonoids as potent COX-2 inhibitors
US7108868B2 (en) 2002-03-22 2006-09-19 Unigen Pharmaceuticals, Inc. Isolation of a dual cox-2 and 5-lipoxygenase inhibitor from acacia
US8034387B2 (en) 2002-04-30 2011-10-11 Unigen, Inc. Formulation of a mixture of free-B-ring flavonoids and flavans for use in the prevention and treatment of cognitive decline and age-related memory impairments
DE60328676D1 (de) * 2002-04-30 2009-09-17 Unigen Pharmaceuticals Inc Formulierung eines gemisches aus flavonoiden und flavanen mit freiem b ring als therapeutisches mittel
MXPA05005794A (es) 2002-12-02 2005-08-16 Hoffmann La Roche Derivados de indazol como antagonistas del factor de liberacion de corticotropina.
PL378120A1 (pl) * 2003-02-14 2006-03-06 Wyeth Heterocyklilo-3-sulfonyloindazole jako ligandy 5-hydroksytryptaminy
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
EP1631304A4 (en) * 2003-04-04 2007-03-21 Unigen Pharmaceuticals Inc FORMULATION OF DUAL CYCLOXYGENASE (COX) AND LIPOXYGENASE (LOX) INHIBITORS FOR THE SKIN CARE OF MAMMALS
US6984652B2 (en) 2003-09-05 2006-01-10 Warner-Lambert Company Llc Gyrase inhibitors
KR100844864B1 (ko) 2004-02-27 2008-07-09 에프. 호프만-라 로슈 아게 헤테로아릴-융합 피라졸로 유도체
CN1922150A (zh) 2004-02-27 2007-02-28 霍夫曼-拉罗奇有限公司 吲唑衍生物以及含有它们的药物组合物
US7844309B2 (en) * 2004-02-27 2010-11-30 Nokia Corporation Exchangeable keymat
JP2007523938A (ja) 2004-02-27 2007-08-23 エフ．ホフマン−ラ　ロシュ　アーゲー ピラゾールの縮合誘導体
US7601847B2 (en) 2004-10-26 2009-10-13 Wyeth Preparation and purification of 4-(indazol-3-yl)phenols
ATE460415T1 (de) * 2004-11-29 2010-03-15 Warner Lambert Co Therapeutische pyrazoloä3,4-büpyridine und - indazole
CN101291913A (zh) * 2005-08-15 2008-10-22 惠氏公司 作为5-羟色胺-6配体的吖嗪基-3-磺酰基吲唑衍生物
CA2619010C (en) * 2005-08-15 2013-10-01 Wyeth Substituted-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands
KR101011956B1 (ko) 2005-08-25 2011-01-31 에프. 호프만-라 로슈 아게 Ｐ３８ ｍαｐ 키나아제 저해제 및 이의 사용 방법
EP1928866A1 (en) 2005-09-05 2008-06-11 Ranbaxy Laboratories Limited Substituted indazoles as inhibitors of phosphodiesterase type-iv
US7915286B2 (en) 2005-09-16 2011-03-29 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
EP2628725A1 (en) * 2005-11-03 2013-08-21 Allergan, Inc. Prostaglandins and analogues as agents for lowering intraocular pressure
BRPI0706523A2 (pt) 2006-01-13 2011-01-04 Wyeth Corp composto de fórmula i; composição farmacêutica; método de tratamento de distúrbios que estão relacionados com ou são afetados pela inibição da recaptação de norepinefrina, o receptor de 5-ht6 ou o receptor de 5-ht2a; método de tratamento de um distúrbio de aprendizado, de um distúrbio cognitivo, de um distúrbio de memória, de um distúrbio de personalidade, de um distúrbio comportamental, de um distúrbio de movimento, de um distúrbio neurodegenerativo, de abstinência de droga, de distúrbio de sono, de um distúrbio alimentar, de uma toxicidade de droga aguda, de um distúrbio cardiovascular, de uma disfunção sexual, de um distúrbio gastrintestinal, de um distúrbio genitourinário, de um distúrbio de dor, de um distúrbio nervoso ou de um distúrbio de sintoma vasomotor; método de tratamento de doença de alzheimer, de um distúrbio de deficiência da atenção, de esquizofrenia, de doença de parkinson, de discinésia tardia, de ataxia, de bradicinésia, de discinésias paroxìsmicas, de sìndrome da perna irrequieta, de tremor, de tremor essencial, de epilepsia, de apoplexia ou de trauma na cabeça; método de tratamento de doença arterial coronariana, de enfarte do miocárdio, de ataque isquêmico transitório, de angina, de fibrilação atrial, de agregação plaquetária, de risco de formação de coágulo sanguìneo, de sìndrome do intestino irritável, de constipação crÈnica, de doença do refluxo gastrintestinal, de dispepsia, de incontinência urinária por estresse ou de incontinência urinária de urgência; método de tratamento de depressão, de distúrbio compulsivo obsessivo, de tendência ao suicìdio, de distúrbio de ansiedade, de distúrbio bipolar, de distúrbio de pánico, de abstinência de nicotina, de abstinência de álcool, de abstinência de cocaìna, de abstinência de heroìna, de abstinência de anfetamina, de abstinência de drogas narcóticas, de insÈnia, de apnéia do sono, de narcolepsia, de distúrbio afetivo sanzonal, de sìndrome da perna irrequieta, de distúrbio de sono de turno de trabalho, de sìndrome da fase do sono retardada, de anorexia nervosa, de bulimia nervosa, de sìndrome do comer noturno, de superalimentação compulsiva, de sìndrome da fadiga crÈnica, de fibromialgia, de neuropatia de dor, de dor antinociceptiva, de sìndrome da dor crÈnica, de neuropatia diabética, de fogacho ou de suor noturno; e uso de um composto
AU2007210073B2 (en) 2006-01-31 2011-10-06 Array Biopharma Inc. Kinase inhibitors and methods of use thereof
BRPI0708337A2 (pt) 2006-02-28 2011-05-24 Helicon Therapeutics Inc pipirazinas terapêutica como inibidores pde4
US8084485B2 (en) 2006-03-31 2011-12-27 Vitae Pharmaceuticals, Inc. 6-(aminoalkyl)indazoles
KR20090006148A (ko) * 2006-04-05 2009-01-14 와이어쓰 5-히드록시트립타민-6 리간드로서의 설포닐-3-헤테로시클릴인다졸 유도체
WO2007120596A1 (en) * 2006-04-12 2007-10-25 Wyeth DIHYDRO[1,4]DIOXINO[2,3-e]INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS
US8012886B2 (en) * 2007-03-07 2011-09-06 Asm Assembly Materials Ltd Leadframe treatment for enhancing adhesion of encapsulant thereto
PT2124944E (pt) 2007-03-14 2012-05-17 Ranbaxy Lab Ltd Derivados de pirazolo[3,4-b]piridina como inibidores de fosfodiesterase
CN102648284B (zh) * 2009-09-18 2014-09-24 株式会社里维松 多酚衍生物及其制造方法
CN102958927A (zh) 2010-05-12 2013-03-06 Abbvie公司 激酶的吲唑抑制剂
CN103709146B (zh) * 2014-01-15 2015-11-25 中国药科大学 一类含苯并咪唑结构的喹啉-4-胺衍生物、其制法及医药用途
WO2021138391A1 (en) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds
CR20230325A (es) 2020-12-30 2023-12-11 Tyra Biosciences Inc Compuestos de indazol como inhibidores de cinasas

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5006520A (en) * 1987-10-13 1991-04-09 Yoshitomi Pharmaceutical Industries, Ltd. Fused pyrazole compounds and pharmaceutical use thereof
EP0338087A4 (en) * 1987-10-13 1991-07-24 Yoshitomi Pharmaceutical Industries, Ltd. Fused pyrazole compounds, process for their preparation, and their medicinal use
US5593997A (en) * 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
AP2001002304A0 (en) * 1996-05-03 2001-12-31 Pfizer Substituted indazole derivatives and related compounds
EA002274B1 (ru) * 1996-06-25 2002-02-28 Пфайзер Инк. Призводные замещенного индазола и их применение в качестве ингибиторов фосфодиэстеразы (фдэ) типа iv и фактора некроза опухоли (фно)
ATE211740T1 (de) * 1996-06-27 2002-01-15 Pfizer Substituierte indazolderivate
PL332187A1 (en) * 1996-09-04 1999-08-30 Pfizer Substitution derivatives of indazole and their application as inhibitors of phosphodiesterase (pde) of iv type and tumor necrosis factor (tnf)
TR200001256T2 (tr) * 1997-11-04 2000-11-21 Pfizer Products Inc. Terapötik olarak aktif bileşimler.

Also Published As

Publication number Publication date
CN1284948A (zh) 2001-02-21
SK6252000A3 (en) 2001-11-06
HUP0004150A2 (hu) 2001-05-28
EA200000488A1 (ru) 2000-10-30
ID23921A (id) 2000-05-25
AP9801375A0 (en) 1998-12-31
HUP0004150A3 (en) 2001-08-28
NO20002129L (no) 2000-07-03
BR9813926A (pt) 2000-09-19
AU754734B2 (en) 2002-11-21
PL340753A1 (en) 2001-02-26
EP1028946A1 (en) 2000-08-23
OA11354A (en) 2003-12-23
BG104450A (en) 2000-12-29
TNSN98200A1 (fr) 2005-03-15
NO20002129D0 (no) 2000-04-26
DZ2640A1 (fr) 2003-03-08
IL135900A0 (en) 2001-05-20
YU25000A (sh) 2003-12-31
HRP20000253A2 (en) 2001-06-30
AR013746A1 (es) 2001-01-10
TR200001234T2 (tr) 2000-08-21
CZ20001621A3 (cs) 2001-08-15
US6391872B1 (en) 2002-05-21
JP2001521926A (ja) 2001-11-13
AP910A (en) 2000-12-05
NZ503918A (en) 2002-03-28
CA2309150A1 (en) 1999-05-14
MA26563A1 (fr) 2004-12-20
WO1999023077A1 (en) 1999-05-14
PE129199A1 (es) 1999-12-16
AU9455298A (en) 1999-05-24

Similar Documents

Publication Publication Date Title
NO20002129L (no) Indazol-bioisoster erstatning av catechol i terapeutiske aktive forbindelser
PT966430E (pt) Compostos anti-inflamatorios
DE69824231D1 (de) Bioadhäsive Tabletten
IS5595A (is) Úðagjöf á virkum efnum
FI972555A7 (fi) Päällystettyjen tablettien valmistus
ID25629A (id) AMINA BISIKLIK (Pecahan dari P-961362)
ID24247A (id) Penjajaran cetakan tunggal
EE9800116A (et) Farmatseutiliselt aktiivsed kinasoliini ühendid
IS5452A (is) Meðferðarlega virk efnasambönd byggð á indazól bíóísóstera skiptum á katekóli í PDE4 lötum
ID23018A (id) Proses baru untuk pembuatan zat-zat yang aktif secara farmakologi
DE59707194D1 (de) Direkttablettierhilfsmittel
IS1901B (is) Efnasambönd til að hindra magasýruseytrun
EE9800298A (et) Farmatseutiliselt kasulikud ühendid
ID26317A (id) Formulasi pelepasan yang diperpanjang
ID22233A (id) Tablet telan yang terdiri dari parasetamol
NO20012965D0 (no) Sulfonyloksazolaminer som terapeutisk aktive forbindelser
NO983090D0 (no) Terapeutiske forbindelser
NO994049D0 (no) Metode for å fremstille farmasöytiske forbindelser
ID23885A (id) Bentuk-bentuk polimorf baru dari cypamfylline
SE9704874D0 (sv) New pharmaceutically active compounds
SE9700660D0 (sv) Pharmaceutically active compounds
KR960037383U (ko) 트랜스퍼용 주행빔의 연결구조
NO20000815D0 (no) Virkestoffholdig vekesystem
ID19095A (id) Senyawa terapeutik fenetanolamina
SE9802539D0 (sv) New pharmaceutically active compounds